良好的雾化疗法在急诊室是否减少了喘儿童住院的需要?
Abdulhadi H Almazroea1, Ahmad H Alharbi2, Bushra A Alawfi1
1Pediatrics, Taibah University, Al-Madinah Al-Munawwarah, SAU.
Cureus
|August 3, 2023
概括
喘的严重程度显著影响儿童的急诊室雾化结果. 与轻度病例相比,中度至严重的喘恶化大大增加了住院率.
科学领域:
- 儿科肺病学 儿科肺病学
- 紧急医疗 紧急医疗
- 呼吸系统护理 呼吸系统护理
背景情况:
- 喘是沙特阿拉伯儿童普遍存在的慢性呼吸道疾病,影响8-25%.
- 对喘恶化进行不充分的急诊室 (ER) 治疗可能导致住院,增加成本和感染风险.
- 雾化疗法的质量取决于患者的位置,药物剂量,氧气流速和治疗时间等因素.
研究的目的:
- 调查影响儿童喘急诊室雾化治疗的因素.
- 评估ER雾化技术与喘儿童住院率之间的关系.
主要方法:
- 在麦地那的妇幼医院 (MCH) 进行了一项观察性,横截面研究.
- 从2021年12月到2023年5月,收集了289名儿童 (2-14岁) 的数据,这些儿童在急诊室患有喘恶化.
- 通过观察和医疗记录收集患者数据,并使用SPSS版本26.0.0进行分析.
主要成果:
- 这项研究包括289名儿童,其中64%是男性,平均年龄为4岁.
- 超过83%的患者患有轻度喘;16.3%患有中度至重度喘.
- 92.4%的患者得到了出院,76.5%的患者得到了适当的雾化剂量.
结论:
- 喘恶化严重程度是儿童喘患者入院的主要决定因素.
- 与轻度喘 (0.4%) 相比,中度至重度喘患者的入院率 (44.7%) 显着更高.
- 雾化技术因素,如患者的位置,氧气流速和药物剂量,对住院率没有显著的临床影响.
相关概念视频
Inhaled Medications
311
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
311
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma: Pathogenesis and Management
446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
Antiasthma Drugs: β2-Adrenoceptor Agonists
307
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
307


